Topic: Prevention and Screening

The Role of FSH in Prostate Cancer

Marc B. Garnick, MD, addresses the question, “Does Follicle Stimulating Hormone (FSH) effect prostate cancer progression and adverse effects to androgen deprivation therapy (ADT), and should we be modulating it?” He presents evidence for both the pro and con sides of this argument.

Read More

Updates on the ERSPC and the PLCO Trials

Dr. Gerald L. Andriole, MD, reviews the designs, materials, and outcomes of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and The European Randomized Study of Screening for Prostate Cancer (ERSPC). He distinguishes between legitimate concerns and inappropriate criticisms of the trials. Also, he explains what this means for the practice of PSA testing.

Read More

The Evolution of Understanding the USPSTF: Recommendations and Controversy

Dr. Neal Shore, MD, FACS, stands in for Deepak A. Kapoor, MD, at the 28th International Prostate Cancer Update, summarizing the history of the United States Preventive Services Task Force (USPSTF) and their Recommendation Grades for disease prevention and screening services. He explains the issues that arise when lawmakers attempt to use USPSTF recommendations as a basis for insurance laws. Specifically, he explains how healthcare policy effects PSA testing.

Read More

Join the GRU Community

- Why Join? -